Developer of targeted therapeutics for cancer. The company uses ZielFind, a target discovery platform to discover new targets. The company's lead molecules, ZB131 fMAb & ZB220 ADC are being developed to target cell surface cytolinker proteins, Plectin-1 as anticancer drugs. The company is also discovering novel cell targets for cardiology, neurology & metabolic diseases with other partners. The company was founded in 2010 and headquartered in Charlottesville, United States. It has raised $26.3M in series a funding, with backing from Center for Innovative Technology, 5Y Capital, Partners Health Care Innovation, Morningside, and others. The company operates in the Life Sciences - Genomics, Life Sciences - Immunotherapy, HealthTech - Life Sciences Tech space. Its offerings span Oncology - Drugs - Diversified.
← All startups
ZielBio
Series ADeveloper of targeted therapeutics for cancer. The company uses ZielFind, a target discovery platform to discover new targets. The company's lead molecules, ZB131 fMAb & ZB220 ADC are being developed to target cell surface cytolinker proteins, Plectin-1 as anticancer drugs. The company is also discovering novel cell targets for cardiology, neurology & metabolic diseases with other partners. The company was founded…
About
Business model
Life Sciences Tech > Research & Development > Drug Discovery > Proteomics,
Oncology > Drugs > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Institutional investors
Center for Innovative Technology5Y CapitalPartners Health Care InnovationMorningsideHHSMass General Brigham Ventures
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Investor directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.